These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 26945298)

  • 41. How Medicare could get better prices on prescription drugs.
    Outterson K; Kesselheim AS
    Health Aff (Millwood); 2009; 28(5):w832-41. PubMed ID: 19643778
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Commercial importation of prescription drugs in the United States: short-run implications.
    Danzon PM; Johnson SJ; Long G; Furukawa MF
    J Health Polit Policy Law; 2011 Apr; 36(2):295-316. PubMed ID: 21543707
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Compared to US practice, evidence-based reviews in Europe appear to lead to lower prices for some drugs.
    Cohen J; Malins A; Shahpurwala Z
    Health Aff (Millwood); 2013 Apr; 32(4):762-70. PubMed ID: 23569057
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Are we living in the end of the blockbuster drug era?
    Debnath B; Al-Mawsawi LQ; Neamati N
    Drug News Perspect; 2010 Dec; 23(10):670-84. PubMed ID: 21180653
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Changes in Retail Prices of Prescription Dermatologic Drugs From 2009 to 2015.
    Rosenberg ME; Rosenberg SP
    JAMA Dermatol; 2016 Feb; 152(2):158-63. PubMed ID: 26606197
    [TBL] [Abstract][Full Text] [Related]  

  • 46. How insurers' bargaining power affects drug prices in Medicare Part D.
    Natl Bur Econ Res Bull Aging Health; 2009; (4):1-2. PubMed ID: 20355274
    [No Abstract]   [Full Text] [Related]  

  • 47. [Risk-sharing schemes: a new paradigm in adopting innovative pharmaceuticals].
    Hammerman A; Greenberg D
    Harefuah; 2012 Jun; 151(6):364-7, 376. PubMed ID: 22991869
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The impact of specialty pharmaceuticals as drivers of health care costs.
    Hirsch BR; Balu S; Schulman KA
    Health Aff (Millwood); 2014 Oct; 33(10):1714-20. PubMed ID: 25288414
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Finding legitimacy for the role of budget impact in drug reimbursement decisions.
    Niezen MG; de Bont A; Busschbach JJ; Cohen JP; Stolk EA
    Int J Technol Assess Health Care; 2009 Jan; 25(1):49-55. PubMed ID: 19126251
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reimbursement issues facing patients, providers, and payers.
    Antman K
    Cancer; 1993 Nov; 72(9 Suppl):2842-5. PubMed ID: 8402516
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rationalizing the introduction and use of pharmaceutical products: The role of managed entry agreements in Central and Eastern European countries.
    Rotar AM; Preda A; Löblová O; Benkovic V; Zawodnik S; Gulacsi L; Niewada M; Boncz I; Petrova G; Dimitrova M; Klazinga N
    Health Policy; 2018 Mar; 122(3):230-236. PubMed ID: 29373186
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A pricing policy towards the sourcing of cheaper drugs in Cyprus.
    Merkur S; Mossialos E
    Health Policy; 2007 May; 81(2-3):368-75. PubMed ID: 16949176
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Payer and Policy Maker Steps to Support Value-Based Pricing for Drugs.
    Bach PB; Pearson SD
    JAMA; 2015 Dec; 314(23):2503-4. PubMed ID: 26619354
    [No Abstract]   [Full Text] [Related]  

  • 54. Achieving cost control, care coordination, and quality improvement through incremental payment system reform.
    Averill RF; Goldfield NI; Vertrees JC; McCullough EC; Fuller RL; Eisenhandler J
    J Ambul Care Manage; 2010; 33(1):2-23. PubMed ID: 20026992
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The pricing of pharmaceuticals: an international comparison.
    Dickson M
    Clin Ther; 1992; 14(4):604-10; discussion 603. PubMed ID: 1525794
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Does Pharmaceutical Pricing Transparency Matter? Examining Brazil's Public Procurement System.
    Kohler JC; Mitsakakis N; Saadat F; Byng D; Martinez MG
    Global Health; 2015 Aug; 11():34. PubMed ID: 26238110
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An assessment of innovative pricing schemes for the communication of value: is price discrimination and two-part pricing a way forward?
    Hertzman P; Miller P; Tolley K
    Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):5-12. PubMed ID: 29186996
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lowering the cost of prescription drugs.
    Jindal B
    J La State Med Soc; 2003; 155(1):51. PubMed ID: 12656276
    [No Abstract]   [Full Text] [Related]  

  • 59. Reimbursement of pharmaceuticals: reference pricing versus health technology assessment.
    Drummond M; Jönsson B; Rutten F; Stargardt T
    Eur J Health Econ; 2011 Jun; 12(3):263-71. PubMed ID: 20803050
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Going over the patent cliff.
    Schommer JC
    Minn Med; 2011 Oct; 94(10):42-3. PubMed ID: 23256283
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.